CompanyMolMed SpA
ATC codeL01
EU authorised2016-08-18
· 10 yr ago
Flags
Conditional approval
EMA EPAR
Evidence dossier ↗
Zalmoxis CONFIRMED
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2) · Hematopoietic Stem Cell Transplantation;Graft vs Host Disease
Current stage: 4 · first detected 2026-06-25
Also known as: zalmoxis
Status timeline
| Date | Body | Status | Stage | Source |
|---|---|---|---|---|
| 2026-06-25 | EMA | withdrawn | 4 | link |
| 2026-06-30 | EMA | withdrawn | 4 | link |
| 2026-07-07 | EMA | withdrawn | 4 | link |
| 2026-07-14 | EMA | withdrawn | 4 | link |
| 2026-07-21 | EMA | withdrawn | 4 | link |
| 2026-07-28 | EMA | withdrawn | 4 | link |
| 2026-08-04 | EMA | withdrawn | 4 | link |
| 2026-08-05 | EMA | withdrawn | 4 | link |
| 2026-08-05 | EMA | withdrawn | 4 | link |
| 2026-08-11 | EMA | withdrawn | 4 | link |
| 2026-08-18 | EMA | withdrawn | 4 | link |